Atreaon picked up $8 million of a planned $20 million initial funding round. According to SEC filings, Morningside Venture is the likely investor in the pharmaceutical startup focused on arthritis.
NEWTON CENTRE, MA, Arthritis-focused pharmaceutical startup Atreaon Inc. has landed $8 million of a planned $20 million initial funding round, according to federal documents.
The single backer on the new round for Newton Centre-based Atreaon is not named in the filing with the U.S. Securities and Exchange Commission, but listed as the only related persons are Reenie McCarthy and Isaac Cheng of Morningside Venture of Boston.
According to published reports, the firm was founded by NYU researchers who designed a progranulin-derived compound that could help treat rheumatoid arthritis and other autoimmune diseases by interfering with TNF signaling. The team formed Atreaon to develop the small protein and related analogs.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
